132 related articles for article (PubMed ID: 38173076)
1. Correction to "Oestrogen-activated autophagy has a negative effect on the anti-osteoclastogenic function of oestrogen".
Cell Prolif; 2024 Feb; 57(2):ecpr13571. PubMed ID: 38173076
[No Abstract] [Full Text] [Related]
2. Oestrogen-activated autophagy has a negative effect on the anti-osteoclastogenic function of oestrogen.
Cheng L; Zhu Y; Ke D; Xie D
Cell Prolif; 2020 Apr; 53(4):e12789. PubMed ID: 32157750
[TBL] [Abstract][Full Text] [Related]
3. Anti-osteoclastogenic activity of isoliquiritigenin via inhibition of NF-κB-dependent autophagic pathway.
Liu S; Zhu L; Zhang J; Yu J; Cheng X; Peng B
Biochem Pharmacol; 2016 Apr; 106():82-93. PubMed ID: 26947453
[TBL] [Abstract][Full Text] [Related]
4. Oestrogen Inhibits Arterial Calcification by Promoting Autophagy.
Peng YQ; Xiong D; Lin X; Cui RR; Xu F; Zhong JY; Zhu T; Wu F; Mao MZ; Liao XB; Yuan LQ
Sci Rep; 2017 Jun; 7(1):3549. PubMed ID: 28615727
[TBL] [Abstract][Full Text] [Related]
5. Immune regulation of bone loss by Th17 cells in oestrogen-deficient osteoporosis.
Zhao R
Eur J Clin Invest; 2013 Nov; 43(11):1195-202. PubMed ID: 24033116
[TBL] [Abstract][Full Text] [Related]
6. Curcumin-activated autophagy plays a negative role in its anti-osteoclastogenic effect.
Ke D; Wang Y; Yu Y; Wang Y; Zheng W; Fu X; Han J; Zhang G; Xu J
Mol Cell Endocrinol; 2020 Jan; 500():110637. PubMed ID: 31678610
[TBL] [Abstract][Full Text] [Related]
7. Blocking of oestrogen signals improves anti-tumour effect regardless of oestrogen receptor alpha expression in cancer cells.
Kajihara N; Ge Y; Seino KI
Br J Cancer; 2023 Oct; 129(6):935-946. PubMed ID: 37537255
[TBL] [Abstract][Full Text] [Related]
8. Modulation of oestrogen receptor activity by oestrogens and anti-oestrogens.
Green S
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):747-51. PubMed ID: 2285586
[TBL] [Abstract][Full Text] [Related]
9. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor.
Ohtake F; Takeyama K; Matsumoto T; Kitagawa H; Yamamoto Y; Nohara K; Tohyama C; Krust A; Mimura J; Chambon P; Yanagisawa J; Fujii-Kuriyama Y; Kato S
Nature; 2003 May; 423(6939):545-50. PubMed ID: 12774124
[TBL] [Abstract][Full Text] [Related]
10. Modelling the effect of GRP78 on anti-oestrogen sensitivity and resistance in breast cancer.
Parmar JH; Cook KL; Shajahan-Haq AN; Clarke PA; Tavassoly I; Clarke R; Tyson JJ; Baumann WT
Interface Focus; 2013 Aug; 3(4):20130012. PubMed ID: 24511377
[TBL] [Abstract][Full Text] [Related]
11. Oestrogen-deficiency induces bone loss by modulating CD14
Collins FL; Stone MD; Turton J; McCabe LR; Wang ECY; Williams AS
BMC Musculoskelet Disord; 2019 Jul; 20(1):326. PubMed ID: 31299941
[TBL] [Abstract][Full Text] [Related]
12. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues.
Zupan J; Komadina R; Marc J
J Biomed Sci; 2012 Mar; 19(1):28. PubMed ID: 22380539
[TBL] [Abstract][Full Text] [Related]
13. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
Helms MW; Packeisen J; August C; Schittek B; Boecker W; Brandt BH; Buerger H
J Pathol; 2005 Jul; 206(3):366-76. PubMed ID: 15892165
[TBL] [Abstract][Full Text] [Related]
14. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.
Kunisue H; Kurebayashi J; Otsuki T; Tang CK; Kurosumi M; Yamamoto S; Tanaka K; Doihara H; Shimizu N; Sonoo H
Br J Cancer; 2000 Jan; 82(1):46-51. PubMed ID: 10638965
[TBL] [Abstract][Full Text] [Related]
15. Sex-specific postnatal development of negative oestrogen feedback in rats.
Döcke F; Rohde W; Freitag J; Dörner G
Exp Clin Endocrinol; 1988 Aug; 91(3):301-10. PubMed ID: 3251770
[TBL] [Abstract][Full Text] [Related]
16. Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha.
Gougelet A; Mueller SO; Korach KS; Renoir JM
J Steroid Biochem Mol Biol; 2007 May; 104(3-5):110-22. PubMed ID: 17478088
[TBL] [Abstract][Full Text] [Related]
17. Effects of naloxone infusion on plasma levels of LH, FSH, and in addition TSH and prolactin in males, before and after oestrogen or anti-oestrogen treatment.
van Bergeijk L; Gooren LJ; van Kessel H; Sassen AM
Horm Metab Res; 1986 Sep; 18(9):611-5. PubMed ID: 3096859
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide regulates oestrogen-activated signalling pathways at multiple levels through cyclic GMP-dependent recruitment of insulin receptor substrate 1.
Falcone S; Mauro L; de Rose G; Paolucci C; Sciorati C; Ando S; Clementi E
Biochem J; 2002 Aug; 366(Pt 1):165-73. PubMed ID: 11978177
[TBL] [Abstract][Full Text] [Related]
19. Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling.
Harrison H; Simões BM; Rogerson L; Howell SJ; Landberg G; Clarke RB
Breast Cancer Res; 2013 Mar; 15(2):R21. PubMed ID: 23497505
[TBL] [Abstract][Full Text] [Related]
20. High-affinity anti-oestrogen binding site distinct from the oestrogen receptor.
Sutherland RL; Murphy LC; San Foo M; Green MD; Whybourne AM; Krozowski ZS
Nature; 1980 Nov; 288(5788):273-5. PubMed ID: 7432524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
